权益ETF系列：震荡调整，关注医药及红利板块的相对机会

Investment Rating - The report maintains an "Overweight" rating for the sector [1] Core Viewpoints - The market is expected to experience a period of volatility, with a focus on relative opportunities in the pharmaceutical and dividend sectors [19][21] - The model predicts a potential shift to a downward trend for the Wande All A Index, indicating a possible adjustment phase in May [19][26] - The pharmaceutical sector is highlighted for its relative stability and potential for returns, while the dividend sector is also expected to perform well after a short-term adjustment [19][21] Summary by Sections A-share Market Overview (May 12-16, 2025) - The top three broad indices were: North Certificate 50 (3.13%), Wande Micro-Pan Daily Equal Weight Index (1.58%), and ChiNext Index (1.38%) [10] - The bottom three indices were: Sci-Tech Innovation 100 (-1.29%), Sci-Tech Innovation 50 (-1.10%), and Sci-Tech Comprehensive Index (-1.00%) [10] A-share Market Outlook (May 19-23, 2025) - The Wande All A Index's daily model shifted from a positive to a negative signal on May 15, suggesting a potential adjustment phase [19][26] - The monthly model for May scored -2.5, indicating a slight adjustment in the A-share market [19][26] - The report anticipates a "V-shaped" market movement, with ongoing pressure on trading volumes [19] Fund Allocation Recommendations - The report suggests a defensive ETF allocation strategy, focusing on the pharmaceutical and dividend sectors for relative returns [19][21]